Starling Oncology annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Starling Oncology Capital Expenditures (CapEx) Growth & History (STLN)
Starling Oncology's capital expenditures (capex) was $3.2M for fiscal 2025.
View full Starling Oncology company overviewStarling Oncology annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.2M | −$589,000 | −15.54% |
| 2024 | 2024-12-31 | $3.8M | −$778,000 | −17.04% |
| 2023 | 2023-12-31 | $4.6M | −$962,000 | −17.40% |
| 2022 | 2022-12-31 | $5.5M | $2.7M | +94.20% |
| 2021 | 2021-12-31 | $2.8M | $1.7M | +138.44% |
| 2020 | 2020-12-31 | $1.2M | — | — |
Starling Oncology quarterly capital expenditures (capex)
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $908,000 | −$300,000 | −24.83% |
| Q1 2026 | 2026-03-31 | $1.0M | $714,000 | +217.68% |
| Q4 2025 | 2025-12-31 | $1.1M | −$695,000 | −39.60% |
| Q3 2025 | 2025-09-30 | $604,000 | $202,000 | +50.25% |
| Q2 2025 | 2025-06-30 | $1.2M | −$618,000 | −33.84% |
| Q1 2025 | 2025-03-31 | $328,000 | −$282,000 | −46.23% |
| Q4 2024 | 2024-12-31 | $1.8M | $894,000 | +103.83% |
| Q3 2024 | 2024-09-30 | $402,000 | −$528,000 | −56.77% |
| Q2 2024 | 2024-06-30 | $1.8M | $889,000 | +94.88% |
| Q1 2024 | 2024-03-31 | $610,000 | −$1.2M | −66.83% |
| Q4 2023 | 2023-12-31 | $861,000 | −$1.1M | −56.84% |
| Q3 2023 | 2023-09-30 | $930,000 | −$260,000 | −21.85% |
| Q2 2023 | 2023-06-30 | $937,000 | −$405,000 | −30.18% |
| Q1 2023 | 2023-03-31 | $1.8M | $837,000 | +83.53% |
| Q4 2022 | 2022-12-31 | $2.0M | $1.1M | +129.05% |
| Q3 2022 | 2022-09-30 | $1.2M | $240,000 | +25.26% |
| Q2 2022 | 2022-06-30 | $1.3M | $935,000 | +229.73% |
| Q1 2022 | 2022-03-31 | $1.0M | $383,000 | +61.87% |
| Q4 2021 | 2021-12-31 | $871,000 | — | — |
| Q3 2021 | 2021-09-30 | $950,000 | — | — |
| Q2 2021 | 2021-06-30 | $407,000 | — | — |
| Q1 2021 | 2021-03-31 | $619,000 | — | — |
Starling Oncology capital expenditures (capex) trends
Over the last five fiscal years, Starling Oncology's capital expenditures (capex) increased from $1.2M to $3.2M, a change of $2.0M. The latest reported quarter, Q2 2026, shows $908,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Starling Oncology source filings ↗